Oppenheimer lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $10 and keeps an Outperform rating on the shares following quarterly results. The most notable update was that ALPHA3’s first update is being pushed back 6 months. Management said that sites were taking longer to recruit patients than anticipated-and they took full responsibility for it, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics price target lowered to $9 from $12 at Baird
- Buy Rating Affirmed for Allogene Therapeutics Amid Strategic Developments and Financial Strength
- Allogene Therapeutics price target lowered to $7 from $9 at Piper Sandler
- Positive Outlook on Allogene Therapeutics Amid ALPHA3 Trial Delays and Market Expansion Potential
- Allogene downgraded to Market Perform from Outperform at Citizens JMP